Top 10 Companies in the Similar Biological Medicinal Products Market (2026): Market Leaders Driving Global Biopharma Growth

MARKET INSIGHTS

Global similar biological medicinal products (biosimilars) market was valued at USD 25.4 billion in 2024. The market is projected to grow from USD 29.1 billion in 2025 to USD 71.9 billion by 2032, exhibiting a CAGR of 12.3% during the forecast period.

Biosimilars are biological products that demonstrate high similarity to approved reference biologics in terms of quality, safety and efficacy. While structurally similar to originator biologics, biosimilars are not identical due to the inherent complexity of biological manufacturing processes involving living cells. These products span therapeutic proteins, monoclonal antibodies and other complex molecules used to treat conditions ranging from cancer to autoimmune disorders.

The market growth is being driven by several key factors: significant cost savings compared to reference biologics (typically 15‑30% lower), expiration of patents for blockbuster biologics, and increasing regulatory approvals across major markets. Recent industry developments include Pfizer’s June 2024 launch of a biosimilar version of a major autoimmune drug in Europe, and Samsung Bioepis’ Q2 2024 FDA approval for its oncology biosimilar. These developments are accelerating market expansion while improving patient access to affordable biologics.

Market Size

The market is projected to reach USD 71.9 billion by 2032, underscoring a robust demand for cost‑effective biologic alternatives. The expanding pipeline of biosimilar approvals, coupled with the erosion of blockbuster biologic exclusivity, is driving this upward trajectory.

Product Definition

Biosimilars are highly similar copies of reference biologics, meeting rigorous analytical, pre‑clinical and clinical criteria to demonstrate comparable safety, efficacy and quality. They differ from generic drugs in that they are not exact replicas due to the complexity of their production from living cells.

Top 10 Companies in the Similar Biological Medicinal Products Market

1️⃣ Sandoz (Novartis)

Headquarters: Basel, Switzerland
Key Offering: Broad portfolio of biosimilars across oncology, autoimmune and endocrine indications.

Sandoz leverages its deep biopharmaceutical expertise to streamline development and bring high‑quality biosimilars to market quickly. The company’s focus on scalable manufacturing and data‑driven analytics positions it to maintain a leading share in the growing biosimilar landscape.

Sustainability & Growth Initiatives: Commitment to reducing carbon footprint through energy‑efficient bioreactors and waste‑minimization programs across its global facilities.

Expanded oncology biosimilar portfolio in 2025.
Investment in continuous bioprocessing technologies.
Strategic partnership with local manufacturers in emerging markets.

2️⃣ Pfizer

Headquarters: New York, USA
Key Offering: Oncology and autoimmune biosimilars, including a newly approved anti‑TNF biosimilar.

Pfizer’s robust pipeline and strong regulatory track record accelerate its biosimilar launch cadence, enhancing access to affordable biologics in high‑demand therapeutic areas.

Sustainability & Growth Initiatives: Focus on green chemistry and renewable energy sourcing for manufacturing sites.

FDA approval of a new oncology biosimilar in Q2 2024.
Strategic collaborations with specialty clinics to drive adoption.
Investment in AI‑driven analytics for product development.

3️⃣ Amgen

Headquarters: Thousand Oaks, USA
Key Offering: Monoclonal antibody biosimilars and insulin analogues.

Amgen’s deep expertise in antibody engineering and strong commercial network underpin its rapid expansion in the biosimilar segment.

Sustainability & Growth Initiatives: Energy‑efficient manufacturing processes and carbon offset programs.

Launch of a biosimilar insulin in 2025.
Expansion of global distribution network.
Investment in bioreactor technology to improve yield.

4️⃣ Samsung Bioepis

Headquarters: Seoul, South Korea
Key Offering: Oncology biosimilars, including a recently approved trastuzumab biosimilar.

Samsung Bioepis’s focus on high‑quality biologics and strategic licensing agreements allows it to capture a significant share of the Asian and global markets.

Sustainability & Growth Initiatives: Adoption of renewable energy sources for manufacturing facilities.

FDA approval of an oncology biosimilar in Q2 2024.
Partnerships with local hospitals for clinical trials.
Investment in continuous bioprocessing.

5️⃣ Biocon

Headquarters: Bangalore, India
Key Offering: Biosimilars for autoimmune and oncology indications.

Biocon’s cost‑effective manufacturing model and strong presence in the Indian market position it as a key player in emerging economies.

Sustainability & Growth Initiatives: Implementation of water‑recycling systems and waste‑to‑energy projects.

Launch of multiple biosimilars in 2025.
Expansion into Latin America through joint ventures.
Investment in R&D for next‑generation biosimilars.

6️⃣ Teva Pharmaceutical Industries

Headquarters: Petah Tikva, Israel
Key Offering: Broad portfolio of biosimilars, including insulin and monoclonal antibodies.

Teva’s global footprint and strong manufacturing capabilities enable rapid scale‑up of biosimilar production.

Sustainability & Growth Initiatives: Commitment to 100% renewable electricity by 2030.

New insulin biosimilar launch in 2025.
Expansion of production capacity in Europe.
Strategic alliances with specialty pharmacies.

7️⃣ Celltrion

Headquarters: Seoul, South Korea
Key Offering: Biosimilars for oncology and autoimmune indications.

Celltrion’s advanced cell‑line engineering and robust regulatory experience support its rapid market entry.

Sustainability & Growth Initiatives: Implementation of green bioprocessing and waste reduction programs.

Launch of a new anti‑PD‑1 biosimilar in 2025.
Expansion into European markets.
Investment in digital biomanufacturing platforms.

8️⃣ Boehringer Ingelheim

Headquarters: Ingelheim, Germany
Key Offering: Biosimilars for oncology, autoimmune and metabolic diseases.

Strong R&D and a robust commercial network underpin Boehringer Ingelheim’s leadership in the biosimilar arena.

Sustainability & Growth Initiatives: Reduction of CO₂ emissions across manufacturing sites.

New biosimilar launch in 2025.
Expansion of production facilities in the EU.
Investment in precision manufacturing.

9️⃣ Viatris

Headquarters: New York, USA
Key Offering: Broad portfolio of biosimilars, including oncology and endocrine indications.

Viatris leverages its global distribution network to accelerate biosimilar adoption worldwide.

Sustainability & Growth Initiatives: Focus on circular economy and waste reduction.

Launch of a new biosimilar insulin in 2025.
Expansion into emerging markets through partnerships.
Investment in sustainable packaging.

🔟 Novartis (Sandoz)

Headquarters: Basel, Switzerland
Key Offering: Extensive biosimilar portfolio across multiple therapeutic areas.

Novartis’s global reach and integrated biomanufacturing capabilities ensure a steady pipeline of high‑quality biosimilars.

Sustainability & Growth Initiatives: Commitment to net‑zero emissions by 2040.

Strategic expansion of biosimilar production in Asia.
Investment in renewable energy for manufacturing sites.
Partnerships with academic institutions for biosimilar research.

Download FREE Sample Report: Similar Biological Medicinal Products Market – View in Detailed Research Report

Get Full Report: Similar Biological Medicinal Products Market – View in Detailed Research Report

Outlook

The biosimilar market is set to reach USD 71.9 billion by 2032, with a steady expansion driven by patent expirations, cost‑effectiveness and regulatory support. Emerging markets, particularly in Asia‑Pacific, are poised to capture a substantial share of the growth, while advanced economies will continue to adopt biosimilars to manage escalating healthcare costs.

Future Trends

Accelerated Regulatory Approvals: Regulatory agencies are streamlining pathways, leading to faster market entry.
Manufacturing Efficiency: Continuous bioprocessing and cell‑line engineering reduce costs by 30‑40% and improve yield.
Therapeutic Expansion: New indications in ophthalmology, neurology and rare diseases are emerging, broadening the biosimilar market.
Strategic Partnerships: Licensing and joint‑venture agreements are becoming essential to navigate complex manufacturing and IP landscapes.
Digital Transformation: AI and data analytics are accelerating product development and post‑market surveillance.

Author
Recent Posts

Rohit k